

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**AID Life Science Holdings Limited**  
**(滙友生命科學控股有限公司)\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8088)**

**SUPPLEMENTAL INFORMATION TO THE 2018 ANNUAL REPORT  
AND 2019 INTERIM REPORT**

References are made to the annual report for the year 31 December 2018 (“**2018 Annual Report**”) of AID Life Science Holdings Limited (the “**Company**” and, together with its subsidiaries, the “**Group**”) published on 29 March 2019 and the interim report for the six months ended 30 June 2019 (“**2019 Interim Report**”) of the Company published on 14 August 2019. Capitalised terms used in this announcement shall have the same meanings as those defined in the 2018 Annual Report unless otherwise defined herein.

The board (the “**Board**”) of directors (the “**Director(s)**”) of the Company wishes to supplement the following information to the financial assets at fair value through profit or loss disclosed on pages 139–142 of the 2018 Annual Report and pages 33–35 of the 2019 Interim Report respectively:

\* *For identification purposes only*

The Group had financial assets at fair value through profit or loss in aggregate amount of approximately HK\$400.9 million and HK\$442.0 million as at 30 June 2019 and 31 December 2018 respectively, representing approximately 70% and 68% of the total assets of the Group as at the respective reporting date. The following table sets out the Group's major investments as at 30 June 2019 and 31 December 2018:

Name of investments	As at 30 June 2019		As at 31 December 2018	
	Fair value at reporting date HK\$'000	Approximate percentage to the total assets of the Group	Fair value at reporting date HK\$'000	Approximate percentage to the total assets of the Group
Zoox ( <i>Note 1</i> ) — unlisted shares	294,758	52%	309,286	48%
China Creative Digital Entertainment Limited (formerly known as HMV Digital China Group Limited) ( <i>Note 2</i> ) — listed shares	3,799	1%	28,739	4%
— convertible bond with interest rate of 5% per annum and maturity date on 25 April 2021	36,120	6%	36,573	6%
Other investments	66,223	11%	67,440	10%
	<b>400,900</b>	<b>70%</b>	<b>442,038</b>	<b>68%</b>

Notes:

#### 1. Zoox Inc. (“Zoox”)

Zoox is principally engaged in robotics and pioneering autonomous mobility-as-a-service. The company is developing a breakthrough, fully automated, electric vehicle fleet and the supporting ecosystem required to bring the service to market at scale. Further information of Zoox were disclosed in the Management Discussion and Analysis section of the 2018 Annual Report. The Group's shareholding were approximately 2.1% and 2.6% of issued share capital of Zoox as at 30 June 2019 and 31 December 2018 respectively.

The investment cost of Zoox is US\$30,000,000 (equivalent to approximately HK\$234,000,000). Upon adoption of IFRS 9, fair value gain of HK\$75,286,000 was recognised for the year ended 31 December 2018 and fair value loss of HK\$14,528,000 was recognised for the six months ended 30 June 2019 in relation to the investment in Zoox.

**2. China Creative Digital Entertainment Limited (“China Creative”, formerly known as HMV Digital China Group Limited) (stock code: 8078)**

China Creative is principally engaged in the distribution and production of films, television programs and music production and artist management services. The Group’s shareholding were approximately 11.1% and 17.6% of issued share capital of China Creative as at 30 June 2019 and 31 December 2018 respectively.

Upon adoption of IFRS 9, fair value loss of HK\$507,764,000 was recognised for the year ended 31 December 2018 and fair value loss of HK\$11,187,000 was recognised for the six months ended 30 June 2019 in relation to the investments in China Creative.

For further information of the business and financial performance of China Creative, please refer to the reports, announcements and publications of China Creative from time to time for updates on its prospects and performances.

Except for investments in Zoox and China Creative, as at 30 June 2019 and 31 December 2018, none of the Group’s individual investment amounted to 10% or more of the total assets of the Group.

Save for the information above, the contents of the 2018 Annual Report and 2019 Interim Report remain unchanged.

By Order of the Board  
**AID Life Science Holdings Limited**  
**Wu King Shiu, Kelvin**  
*Chairman*

Hong Kong, 27 September 2019

*As at the date of this announcement, the Directors are:*

*Chairman and Non-Executive Director:*                      *Wu King Shiu, Kelvin*

*Executive Directors:*    *Chan Suet Ngan, Hu Kenneth and  
Qian Alexandra Gaochuan*

*Independent Non-Executive Directors:*                      *Yuen Kwok On, Matsumoto Hitoshi and  
Yau Chung Hang*

*This announcement, for which the Directors collectively and individually accept full responsibility, includes particulars given in compliance with the GEM Listing Rules for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief (i) the information contained in this announcement is accurate and complete in all material respects and not misleading or deceptive; and (ii) there are no other matters the omission of which would make any statement in this announcement misleading.*

*This announcement will remain on the GEM website at [www.hkgem.com](http://www.hkgem.com) on the “Latest Company Announcements” page for at least 7 days from the date of its posting and on the website of the Company at [www.8088inc.com](http://www.8088inc.com).*